Stock GNPX GENPREX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genprex, Inc.

Equities

GNPX

US3724462037

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 08:05:55 08/05/2024 pm IST 		5-day change 1st Jan Change
2.422 USD -2.36% Intraday chart for Genprex, Inc. +7.15% -73.68%
03/04 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer CI
02/04 Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System CI

Valuation

Fiscal Period: December 2019 2020 2021 2023 2024 2025 2026
Capitalization 1 6.164 178.7 62.63 13.67 5.205 - -
Enterprise Value (EV) 1 6.164 178.7 62.63 13.67 5.205 5.205 5.205
P/E ratio -0.48 x -8.14 x -3.12 x - -0.43 x -0.89 x -
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA - - - - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 482 1,076 1,195 1,486 2,099 - -
Reference price 2 12.80 166.0 52.40 9.200 2.480 2.480 2.480
Announcement Date 30/03/20 26/03/21 30/03/22 01/04/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - -
EBITDA - - - - - - - -
EBIT 1 - -17.96 -19.58 -23.83 -31.08 -24.21 -26.01 -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 - - -19.6 - - -24.21 -26.01 -
Net income 1 -10.65 -17.94 -19.6 -23.74 -30.86 -24.21 -32 -40.24
Net margin - - - - - - - -
EPS 2 -26.40 -20.40 -16.80 - - -5.770 -2.780 -
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 30/03/20 26/03/21 30/03/22 31/03/23 01/04/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 - -5.676 -5.723 -5.175 -6.111 -6.822 -5.987 -6.053 -6.053 -6.053 -6.053 -
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - -5.682 -5.722 - - - - -6.053 -6.053 -6.053 -6.053 -
Net income 1 -3.438 -5.682 -5.722 -5.169 -6.083 -6.766 -5.929 -6.053 -6.053 -6.053 -6.053 -
Net margin - - - - - - - - - - - -
EPS 2 - -4.800 -4.800 - - - - -2.540 -1.840 -1.260 -0.9600 -0.8600
Dividend per Share - - - - - - - - - - - -
Announcement Date 15/11/21 30/03/22 13/05/22 12/08/22 14/11/22 31/03/23 01/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 2.34 - - - 0.02 - -
Capex / Sales - - - - - - - -
Announcement Date 30/03/20 26/03/21 30/03/22 31/03/23 01/04/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.48 USD
Average target price
165 USD
Spread / Average Target
+6,553.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GENPREX, INC. Stock Genprex, Inc.
-73.68% 5.2M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+4.31% 106B
ARGENX SE Stock argenx SE
+6.87% 23.47B
BIONTECH SE Stock BioNTech SE
-14.21% 21.9B
GENMAB A/S Stock Genmab A/S
-6.73% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.40% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.10% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.76% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+323.80% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GNPX Stock
  4. Financials Genprex, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW